P/E Ratio

Riding a wave of strong financial performance, Knowles Corp. prepares to outline its future in Medtech, Defense, and Industrial markets to investors.

With shareholder approval secured, Montage Gold is one step away from acquiring African Gold, a move set to create a new powerhouse in West Africa's gold sector.

Activist investor Veradace Partners demands Repay scrap its KUBRA deal, alleging a breach of fiduciary duty and widespread shareholder opposition.

Amid claims of undervaluation and AI-driven momentum, the cybersecurity giant escalates its share repurchase plan, signaling deep confidence in its future.

CanTex Capital's landmark sale of a 1.3M sq ft portfolio to Partners Group highlights booming demand for DFW's strategic shallow bay industrial assets.

VanEck's new VEFA fund uses analyst upgrades to pick international stocks, aiming to capture returns as global markets gain on the concentrated US.

Avory & Co. enters the crowded ETF market with AVRY, an actively managed fund shunning trends for a concentrated portfolio of high-quality stocks.

Rithm Capital declared its 52nd straight dividend. Is its high yield and analyst praise enough to overcome recent stock woes and market skepticism?

The non-prime lender struck a deal with lenders to ensure liquidity, but it comes at a high price amid massive loan losses and scrutiny of its LendCare unit.

As AI valuations soar and IPOs loom, one veteran wealth manager warns of a familiar pattern. Are we witnessing innovation or another dot-com-style bubble?

As MediciNova execs meet investors at the ROTH Conference, all eyes are on pivotal updates for its ALS, MS, and NAFLD drug candidates.

As automation demand soars, ATS Corp. will meet investors to outline its strategy for navigating market shifts and capitalizing on life sciences growth.

A new survey finds companies are dynamically adjusting investment hurdles in response to market chaos, leveraging technology to navigate an uncertain world.

Transcat appoints decorated industrial leader Jaime Irick as its new CEO, signaling a strategic pivot toward accelerated growth and market expansion.

Burford Capital's leadership invests millions from their own pay, claiming shares are deeply discounted. But will the market agree with their bold move?

A new report reveals a puzzling slowdown in CLO issuance despite low credit yields. Experts analyze the hidden headwinds and shifting investor strategies.

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

Titan International beat expectations in Q4, driven by a 21% surge in its construction division, and now eyes a strong 2026 as OEM destocking ends.

Apellis Pharmaceuticals reports its first profitable year on strong SYFOVRE and EMPAVELI sales, but faces pressure to maintain momentum amid competition.

The French banking giant finalizes a major capital reduction and progresses on a new buyback, signaling strong confidence and rewarding investors.